In many preclinical studies, researchers minimise variability by tightly controlling factors. This reduces experimental noise, which increases the chance of detecting small statistically significant effects. However, this strategy introduces several risks.

To address standardisation fallacy, several approaches have been proposed:
Systematic Heterogenisation of Experiments
Instead of minimising variability, researchers deliberately vary certain conditions (e.g., multiple experimenters, cages, etc.). This increases robustness.
Multi-Laboratory Designs
Running the same experiment across several labs can reveal whether an effect holds across contexts.
Randomisation & blocking
Structured experimental designs (e.g., block designs) allow variability to be incorporated while still controlling statistical power.
Larger and More Representative Samples
Including both sexes, different strains, or broader biological variation improves translational relevance.
Robust Statistical Approaches
Hierarchical or mixed-effects models can explicitly model variability rather than eliminate it.
Traditional goal → maximise internal validity & power.
Emerging goal → balance internal validity, reproducibility, & translational relevance.
💡 Detecting a small effect in a perfectly controlled system may be useful, but detecting an effect that persists across realistic variability is much more informative for translation to humans.
It is really worthwhile to seek a statistician’s advice during the study design phase. We provide biostatistics mentoring for biotech and medtech teams, drawing on 35+ years of experience: https://lnkd.in/eT6DdMre
